Lee Sungho, Karas Patrick J, Hadley Caroline C, Bayley V James C, Khan A Basit, Jalali Ali, Sweeney Alex D, Klisch Tiemo J, Patel Akash J
Department of Neurosurgery, Baylor College of Medicine, Houston, TX 77030, USA.
Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
Cancers (Basel). 2019 Oct 24;11(11):1633. doi: 10.3390/cancers11111633.
Mutations in the () gene were among the first genetic alterations implicated in meningioma tumorigenesis, based on analysis of neurofibromatosis type 2 (NF2) patients who not only develop vestibular schwannomas but later have a high incidence of meningiomas. The gene product, merlin, is a tumor suppressor that is thought to link the actin cytoskeleton with plasma membrane proteins and mediate contact-dependent inhibition of proliferation. However, the early recognition of the crucial role of mutations in the pathogenesis of the majority of meningiomas has not yet translated into useful clinical insights, due to the complexity of merlin's many interacting partners and signaling pathways. Next-generation sequencing studies and increasingly sophisticated -deletion-based and models have helped elucidate the consequences of merlin loss in meningioma pathogenesis. In this review, we seek to summarize recent findings and provide future directions toward potential therapeutics for this tumor.
基于对2型神经纤维瘤病(NF2)患者的分析,()基因的突变是最早被认为与脑膜瘤肿瘤发生有关的基因改变之一。这些患者不仅会发生前庭神经鞘瘤,而且后期患脑膜瘤的几率很高。该基因的产物默林是一种肿瘤抑制因子,被认为能将肌动蛋白细胞骨架与质膜蛋白联系起来,并介导接触依赖性增殖抑制。然而,由于默林众多相互作用的伙伴和信号通路的复杂性,早期对大多数脑膜瘤发病机制中突变关键作用的认识尚未转化为有用的临床见解。下一代测序研究以及越来越复杂的基于缺失的和模型有助于阐明默林缺失在脑膜瘤发病机制中的后果。在这篇综述中,我们试图总结近期的研究发现,并为该肿瘤潜在治疗方法提供未来方向。